All In Biotech

Drug Trial Radar · NCT06137742

A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

A PHASE 1 / 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF SINGLE ESCALATING DOSES OF PF-07868489 IN HEALTHY ADULT PARTICIPANTS AND, ADDITIONALLY, CLINICAL ACTIVITY OF REPEAT DOSES IN PARTICIPANTS WITH PULMONARY ARTERIAL HYPERTENSION

Last checked: Nov 20, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

97

Actual

Start

Nov 17, 2023

Primary completion

Jul 31, 2026

Study completion Jul 31, 2026

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Nov 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of the study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH). Part A: An investigator- and participant-blind, sponsor-open, placebo-controlled, single ascending dose study to assess the safety, tolerability, and pharmacokinetics (PK) of PF-07868489 in healthy adult participants. Part B: A 24-week, randomized, double blind, placebo-controlled study to assess the safety, tolerability, PK, and pharmacodynamics (PD) of PF-07868489 in adult participants with PAH.

Conditions

  • Pulmonary Arterial Hypertension

Interventions

  • PF-07868489Drug

    Experimental Treatment

  • Placebo for PF-07868489Drug

    Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to Day 113.
  2. Number of Participants With Change From Baseline in Laboratory Tests ResultsTime frame: Baseline up to Day 113
  3. Number of Participants With Vital Sign AbnormalitiesTime frame: Baseline up to Day 113
  4. Number of Participants With Change From Baseline in Electrocardiogram (ECG) ParametersTime frame: Baseline up to Day 113
  5. Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Baseline up to Day 253
  6. Number of Participants With Change From Baseline in Laboratory Tests ResultsTime frame: Baseline up to Day 253
  7. Number of Participants With Vital Sign AbnormalitiesTime frame: Baseline up to Day 253
  8. Number of Participants With Change From Baseline in Electrocardiogram (ECG) ParametersTime frame: Baseline up to Day 253
  9. Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week24Time frame: Baseline, Week 24

Locations

46 sites in 12 countries. Site status is shown where the registry gives one.

  • Anaheim Clinical Trials, LLC

    Anaheim, California

  • UCI Health - Costa Mesa

    Costa Mesa, California

  • UCI Health Center for Innovative Health Therapies (CIHT)

    Orange, California

  • University of California, Irvine Medical Center

    Orange, California

  • UCSF Health St. Mary's Hospital

    San Francisco, California

  • UCSF Helen Diller Medical Center at Parnassus Heights

    San Francisco, California

  • Icahn school of medicine at Mount Sinai

    New York, New York

  • Mount Sinai Hospital

    New York, New York

  • Eastowne 100 Medical Office Building

    Chapel Hill, North Carolina

  • Eastowne Medical Office Building - Clinical Research Unit

    Chapel Hill, North Carolina

  • UNC Health - Eastowne Medical Office

    Chapel Hill, North Carolina

  • UNC Hospitals

    Chapel Hill, North Carolina

  • Investigational Drug Services Pharmacy

    Morrisville, North Carolina

  • Medical University of South Carolina - Nexus

    Charleston, South Carolina

  • Medical University of South Carolina - Radiology

    Charleston, South Carolina

  • Medical University of South Carolina

    Charleston, South Carolina

  • Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • Pulmonary Hypertension Research Queensland Pty Ltd

    Auchenflower, Queensland, Australia

  • Wesley Research Institute

    Auchenflower, Queensland, Australia

  • Université Libre de Bruxelles - Hôpital Erasme

    Brussels, Bruxelles-capitale, Région de, Belgium

  • UZ Leuven

    Leuven, Vlaams-brabant, Belgium

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China

  • The Second Xiangya Hospital of Central South University

    Changsha, Hunan, China

  • Zhongda Hospital Southeast University

    Nanjing, Jiangsu, China

  • Shanghai Pulmonary Hospital

    Shanghai, Shanghai Municipality, China

  • Vseobecna fakultni nemocnice v Praze

    Prague, Czechia

  • CHRU de Brest

    Brest, Finistère, France

  • CHRU de Brest

    Brest, Finistère, France

  • Centre Hospitalier Universitaire de Saint Étienne - Hôpital Nord

    Saint Priest En Jarez, Pays de la Loire Region, France

  • Thoraxklinik-Heidelberg gGmbH

    Heidelberg, Baden-Wurttemberg, Germany

  • Universitätsklinikum Regensburg

    Regensburg, Bavaria, Germany

  • UKGM Gießen/Marburg

    Giessen, Hesse, Germany

  • Universitätsmedizin Greifswald

    Greifswald, Mecklenburg-Vorpommern, Germany

  • Universitaetsklinikum Carl Gustav Carus, Technischen Universitaet Dresden

    Dresden, Saxony, Germany

  • Fondazione IRCCS Policlinico San Matteo

    Pavia, Italy

  • National Hospital Organization Okayama Medical Center

    Okayama, Japan

  • Kobe University Hospital

    Kobe, Hyōgo, Japan

  • St. Marianna University Hospital

    Kawasaki, Kanagawa, Japan

  • Tohoku University Hospital

    Sendai, Miyagi, Japan

  • Gachon University Gil Medical Center

    Namdong-gu, Incheon-gwangyeoksi [incheon], South Korea

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.